Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Share :
Published: 26 Oct 2026
Views: 88
Rating:
Save
Dr Ferdinandos Skoulidis - The University of Texas MD Anderson Cancer Center, Houston, USA

Prof Ferdinandos Skoulidis speaks to ecancer about the primary analysis of the phase III Krascendo 1 trial, which compared divarasib, a next-generation KRAS G12C inhibitor, with sotorasib or adagrasib in patients with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).

Among 338 patients, divarasib significantly improved progression-free survival, extending median progression-free survival from 5.7 to 9.8 months, and overall survival, increasing median overall survival from 12.0 to 17.7 months.

The objective response rate was also higher with divarasib, at 58.4% compared with 32.3% with sotorasib or adagrasib.

Divarasib demonstrated a manageable safety profile. Grade 3–4 treatment-related adverse events occurred in 24.6% of patients receiving divarasib compared with 34.5% in the control group.

Treatment discontinuations due to treatment-related adverse events were also less frequent with divarasib (4.8% vs 11.7%).

Prof Skoulidis says that these findings demonstrate significant improvements in progression-free and overall survival with divarasib compared with currently available KRAS G12C inhibitors, supporting its potential as a new standard of care for previously treated advanced KRAS G12C-mutated NSCLC.

This information is intended for health care professionals only. The information is not intended for US health care professionals.

Related Videos

Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer ( Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA )
26 Oct 2026

Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma

Dr Giulia Pasello - University of Padua, Padua, Italy
Pembrolizumab plus chemotherapy shows pathological responses in resectable pleural mesothelioma ( Dr Giulia Pasello - University of Padua, Padua, Italy )
6 Oct 2026

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

Dr William William Jr - Oncoclínicas, São Paulo, Brazil
Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC ( Dr William William Jr - Oncoclínicas, São Paulo, Brazil )
18 Sep 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Dr Giannis Mountzios - The University of Athens, Athens, Greece
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )
1 Jun 2026

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance

Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance ( Dr Jinhui Xue - Sun Yat-sen University Cancer Center, Guangzhou, China )
15 Apr 2026

Cracking the code: Bispecific immunotherapy in small cell lung cancer

Prof Helena Linardou - Metropolitan Hospital, Athens, Greece
Cracking the code: Bispecific immunotherapy in small cell lung cancer ( Prof Helena Linardou - Metropolitan Hospital, Athens, Greece )
13 Apr 2026

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC ( Dr Li Zhang - Sun Yat-sen University Cancer Center, Guangzhou, China )
20 Oct 2025

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced

Prof Nicolas Girard - Institut Curie, Paris, France
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )
7 Apr 2025